

Supplemental Table 1. Clinical characteristics of non-hospitalized patients with Long COVID-19 and recruited at the Primary Healthcare Center Doctor Pedro Laín Entralgo (Madrid, Spain) with the collaboration of non-profit Spanish Association of Patients with Long-COVID (Long-COVID-ACTS). The duration of signs and symptoms was divided in periods of less than 3 months (12 weeks), between 3 and 6 months, between 6 and 9 months, or more than 9 months.

Patient's ID	Age (years)	Gender (M/F)	Blood Group (ABO, Rh±)	Days from clinical onset to sample	Days with COVID-19 symptoms	SARS-CoV-2 qRT-PCR	SARS-CoV-2 IgGs	Signs and symptoms during acute COVID-19									
								Fever (°C)	Oxygenation (%)	Cough (months)	Expectoration (months)	Hemoptysis (months)	Malaise (months)	Lethargy (months)	Migraine	Arthralgia (months)	Myalgia (months)
1	33	F	UN	346	346	YES	YES	38	88	NO	NO	NO	>9	>9	NO	NO	>9
2	31	F	B +	352	352	NO	YES	UN	UN	NO	NO	NO	>9	>9	YES	>9	>9
3	45	F	A +	347	347	YES	YES	38	99	>9	NO	NO	>9	<3	NO	NO	NO
4	48	F	UN	358	358	YES	YES	37.8	96	>9	NO	NO	6-9	3-6	NO	>9	>9
5	43	M	UN	342	342	YES	YES	UN	UN	NO	NO	NO	>9	NO	YES	>9	>9
6	42	F	A +	349	349	YES	YES	38	92	6-9	<3	NO	>9	3-6	YES	>9	>9
7	55	F	O-	348	348	NO	YES	UN	UN	NO	6-9	NO	>9	NO	NO	>9	>9
8	50	F	O +	192	192	YES	NO	39.7	UN	6-9	6-9	NO	6-9	NO	NO	6-9	6-9
9	33	M	O +	336	336	NO	YES	38	96	3-6	>9	NO	NO	>9	YES	NO	<3
10	57	F	O +	351	351	YES	YES	38	92	<3	<3	NO	>9	>9	NO	>9	>9
11	UN	F	A +	194	194	YES	NO	38.5	93	>9	NO	>9	>9	>9	NO	>9	>9
12	46	F	O +	345	345	YES	YES	UN	UN	NO	NO	NO	3-6	<3	NO	>9	>9
13	42	F	O +	341	341	YES	YES	37.7	93	NO	NO	NO	>9	>9	YES	>9	>9
14	46	F	A +	349	349	YES	NO	38	90	3-6	NO	NO	>9	>9	NO	>9	>9
15	41	F	A +	347	347	NO	YES	UN	88	>9	NO	NO	>9	>9	NO	<3	6-9
16	37	F	O +	311	311	YES	YES	38	93	NO	NO	NO	>9	NO	YES	>9	>9
17	42	F	O +	350	350	NO	YES	40	90	NO	NO	NO	>9	>9	NO	>9	>9
18	40	F	O +	358	358	YES	YES	38.5	94	>9	6-9	NO	>9	>9	NO	6-9	>9
19	33	M	A +	356	356	YES	YES	UN	UN	NO	NO	NO	NO	NO	NO	NO	NO
20	33	F	A +	171	171	YES	NO	37.5	91	NO	NO	NO	3-6	3-6	NO	NO	3-6
21	39	F	O +	348	348	YES	YES	38.6	UN	>9	>9	NO	>9	>9	YES	>9	>9
22	42	F	A +	358	358	YES	YES	37.7	92	3-6	NO	NO	>9	3-6	NO	NO	6-9
23	44	F	A +	369	369	NO	YES	37.7	95	3-6	>9	NO	>9	>9	YES	>9	>9
24	UN	F	A +	352	352	YES	YES	37.7	94	3-6	<3	NO	>9	>9	YES	>9	>9
25	52	F	AB +	366	366	YES	NO	UN	UN	>9	6-9	NO	3-6	>9	NO	6-9	6-9
26	44	F	A +	150	150	NO	YES	38	99	3-6	3-6	<3	6-9	6-9	NO	6-9	6-9
27	UN	F	O +	179	179	NO	NO	37.8	96	<3	NO	NO	6-9	6-9	NO	6-9	3-6
28	48	M	A +	357	357	YES	YES	39	93	NO	NO	NO	NO	NO	NO	3-6	NO
29	33	F	A +	334	334	YES	NO	39.1	92	3-6	3-6	NO	>9	>9	NO	NO	>9
30	40	F	O +	360	360	YES	NO	37.7	93	<3	<3	NO	>9	>9	YES	>9	>9

M: male; F: female; UN: Unknown.

Supplemental Table 1 (continuation).

Patient's ID	Signs and symptoms during acute COVID-19												
	Asthenia (months)	Anosmia (months)	Ageusia (months)	Dermatological injuries (months)	Odynophagia (months)	Dyspnea (months)	Pneumonia	Pleuritic chest pain (months)	Conjunctivitis (months)	Diarrhea (months)	Dysphagia (months)	Abdominal pain (months)	Pyrosis /Reflux (months)
1	>9	>9	>9	>9	<3	>9	YES	>9	>9	>9	NO	>9	>9
2	>9	NO	NO	NO	NO	>9	NO	>9	NO	NO	NO	NO	3-6M
3	>9	<3	<3	NO	>9	>9	YES	6-9	NO	6-9	NO	NO	6-9
4	>9	NO	NO	<3	>9	>9	NO	>9	6-9	>9	NO	>9	NO
5	>9	NO	NO	>9	NO	>9	NO	>9	6-9	<3	NO	3-6	<3
6	>9	NO	NO	>9	>9	>9	NO	>9	<3	3-6	<3	6-9	NO
7	>9	<3	<3	<3	>9	NO	NO	>9	NO	6-9	>9	>9	>9
8	6-9	NO	6-9	3-6	NO	6-9	NO	NO	NO	6-9	NO	NO	6-9
9	>9	<3	<3	NO	<3	>9	NO	NO	NO	<3	NO	<3	>9
10	>9	NO	NO	NO	<3	>9	NO	NO	NO	NO	NO	NO	NO
11	>9	6-9	6-9	>9	>9	NO	NO	>9	>9	>9	>9	>9	>9
12	3-6	<3	<3	<3	>9	>9	NO	>9	NO	6-9	6-9	6-9	>9
13	NO	NO	NO	>9	>9	>9	NO	NO	>9	NO	NO	NO	>9
14	>9	3-6	3-6	3-6	6-9	3-6	NO	NO	NO	6-9	3-6	3-6	>9
15	>9	>9	>9	NO	>9	6-9	NO	NO	NO	6-9	NO	3-6	NO
16	>9	NO	NO	NO	NO	>9	NO	>9	NO	<3	3-6	NO	>9
17	>9	3-6	3-6	6-9	>9	>9	NO	>9	NO	<3	3-6	NO	6-9
18	>9	<3	<3	<3	<3	<3	NO	>9	<3	NO	<3	3-6	NO
19	>9	NO	NO	NO	NO	NO	NO	>9	NO	3-6	NO	NO	3-6
20	3-6	NO	NO	3-6	3-6	3-6	NO	3-6	NO	3-6	3-6	<3	NO
21	>9	>9	>9	NO	>9	>9	NO	>9	NO	>9	>9	>9	>9
22	>9	NO	NO	NO	<3	>9	NO	>9	<3	<3	NO	NO	NO
23	>9	NO	NO	<3	>9	>9	NO	>9	NO	NO	NO	NO	6-9
24	>9	<3	<3	NO	<3	>9	NO	>9	NO	<3	NO	NO	NO
25	>9	NO	<3	>9	NO	>9	NO	>9	>9	NO	NO	NO	>9
26	6-9	6-9	NO	6-9	6-9	6-9	NO	6-9	NO	<3	3-6	NO	6-9
27	>9	NO	NO	NO	<3	NO	NO	6-9	NO	NO	NO	6-9	NO
28	>9	NO	NO	6-9	NO	>9	NO	NO	NO	NO	NO	NO	NO
29	>9	NO	NO	>9	NO	>9	YES	>9	NO	>9	NO	NO	>9
30	>9	<3	<3	<3	>9	>9	NO	>9	NO	<3	<3	<3	NO

Supplemental Table 1 (continuation).

Patient's ID	COVID-19 Treatment	Comorbidities								T3/T4 levels altered after COVID (months)
		Autoimmune disease	Diabetes mellitus	DM onset after COVID (months)	Dyslipidemia	Arterial hypertension	Asthma COPD	Cardiovascular disease	Hypothyroidism	
1	LVX; AZM; LMWH; CS; HCQ	NO	NO	NO	NO	NO	NO	NO	NO	NO
2	CRO; LVX; AZM; HCQ; 25(OH)D	NO	NO	NO	NO	NO	NO	NO	NO	NO
3	AZM; CS; HCQ; 25(OH)D	RA	NO	>9	NO	NO	NO	NO	YES	NO
4	NO	NO	NO	NO	YES	NO	NO	NO	NO	NO
5	AZM; LMWH; CS; 25(OH)D	NO	NO	NO	NO	NO	NO	NO	NO	NO
6	AZM; LMWH; CS; CH; 25(OH)D	NO	NO	NO	NO	NO	YES	NO	NO	NO
7	NO	SS	NO	NO	YES	NO	NO	NO	NO	NO
8	AMC	NO	NO	NO	NO	NO	NO	NO	NO	NO
9	AZM; LMWH; HCQ; 25(OH)D	NO	NO	NO	YES	NO	YES	NO	NO	NO
10	LVX; AZM; CS	NO	NO	NO	NO	NO	YES	NO	NO	NO
11	AZM; 25(OH)D	MCTD	NO	>9	NO	NO	NO	NO	YES	NO
12	AMC; CS	RD	NO	NO	NO	NO	NO	NO	NO	NO
13	NO	NO	NO	NO	YES	NO	NO	NO	NO	NO
14	AZM; 25(OH)D	RD	NO	NO	YES	YES	NO	NO	YES	3-6
15	CS	NO	NO	NO	YES	NO	NO	NO	YES	>9
16	CS	PsO	NO	NO	NO	NO	NO	NO	NO	NO
17	AZM; CS; 25(OH)D	NO	NO	NO	NO	NO	NO	NO	NO	NO
18	LVX; AZM; CS	NO	NO	NO	NO	NO	NO	NO	NO	NO
19	25(OH)D	NO	NO	NO	NO	NO	NO	NO	NO	NO
20	CS	NO	NO	NO	NO	NO	NO	NO	NO	NO
21	AMC; CRO; AZM; CS; 25(OH)D	NO	NO	NO	NO	NO	NO	NO	NO	NO
22	NO	NO	NO	NO	NO	NO	NO	NO	YES	6-9
23	AZM; CS; 25(OH)D	NO	NO	NO	YES	NO	NO	NO	NO	<3
24	AZM; LMWH; HCQ	NO	NO	NO	NO	NO	NO	NO	NO	NO
25	LVX; CS	PsO	NO	>9	YES	YES	YES	NO	YES	NO
26	AZM	NO	NO	NO	NO	NO	YES	NO	NO	NO
27	NO	HasTh	NO	NO	NO	NO	NO	YES	YES	6-9
28	CRO; LVX; AZM; HCQ; LPV/r; 25(OH)D	NO	NO	NO	NO	NO	NO	NO	NO	NO
29	AZM; CS; HCQ; LPV/r	PsO	NO	NO	NO	NO	NO	NO	NO	NO
30	AMC; LMWH; HCQ	NO	NO	NO	YES	YES	NO	NO	NO	NO

25(OH)D, vitamin D; AMC, Amoxicillin/Clavulanate; AZM, Azithromycin; COPD, Chronic Obstructive Pulmonary Disease; CRO, Ceftriaxone; CS, Corticosteroids; DM, Diabetes mellitus; HasThy, Hashimoto's Thyroiditis; HCQ, Hydroxychloroquine; LPV/r, Lopinavir/Ritonavir; LMWH, Low Molecular Weight Heparin; LVX, Levofloxacin; MCTD, Mixed Connective Tissue Disease; PsO, Psoriasis; SS, Sjögren's Syndrome; RA, Rheumatoid Arthritis; RD, Raynaud's Disease; T3, Triiodothyronine; T4, Thyroxine.

Supplemental Table 1 (continuation).

Patient's ID	Long-COVID signs and symptoms													
	Bradypsychia (months)	Cacosmia (months)	Paresthesia (months)	Xerostomia (months)	Tinnitus (months)	Dysphonia/Aphonia (months)	Earache (months)	Hearing loss (months)	Diplopia (months)	Eyeache (months)	Headache (months)	Neck/back-ache	Poor concentration (months)	Memory failure (months)
1	>9	>9	>9	>9	NO	>9	>9	NO	NO	>9	>9	>9	>9	>9
2	>9	NO	>9	NO	NO	NO	NO	NO	NO	>9	>9	NO	>9	>9
3	NO	NO	>9	NO	NO	NO	6-9	NO	NO	>9	NO	NO	NO	NO
4	3-6	NO	6-9	>9	NO	>9	NO	NO	3-6	NO	3-6	>9	>9	>9
5	NO	NO	>9	NO	NO	NO	<3	NO	NO	NO	6-9	>9	NO	NO
6	>9	6-9	>9	NO	>9	<3	>9	NO	NO	3-6	>9	>9	>9	>9
7	>9	NO	6-9	>9	NO	>9	<3	NO	NO	6-9	>9	>9	6-9	>9
8	6-9	6-9	6-9	6-9	6-9	NO	NO	6-9	NO	NO	6-9	NO	6-9	6-9
9	>9	NO	NO	NO	>9	NO	NO	NO	NO	>9	>9	>9	>9	>9
10	>9	NO	NO	>9	NO	3-6	NO	NO	NO	NO	NO	>9	>9	>9
11	>9	>9	>9	>9	>9	>9	>9	>9	>9	>9	>9	>9	>9	>9
12	>9	>9	>9	>9	NO	>9	NO	NO	NO	6-9	3-6	>9	6-9	>9
13		NO	NO	NO	NO	>9	NO	NO	NO	>9	>9	>9	>9	>9
14	6-9	3-6	6-9	>9	6-9	6-9	3-6	>9	NO	6-9	>9	>9	>9	>9
15	>9	<3	<3	NO	>9	<3	NO	NO	NO	NO	>9	>9	>9	>9
16	>9	NO	>9	NO	>9	NO	6-9	NO	NO	NO	>9	>9	>9	>9
17	>9	NO	>9	>9	NO	>9	NO	NO	NO	>9	>9	>9	>9	>9
18	6-9	<3	<3	NO	3-6	<3	<3	NO	NO	6-9	>9	3-6	6-9	6-9
19	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
20	3-6	<3	<3	NO	NO	NO	NO	3-6	NO	NO	3-6	NO	3-6	3-6
21	NO	6-9	>9	>9	>9	>9	>9	NO	NO	NO	>9	>9	>9	>9
22	3-6	NO	NO	NO	NO	NO	NO	<3	NO	3-6	3-6	NO	3-6	3-6
23	6-9	6-9	>9	>9	NO	NO	NO	NO	NO	>9	>9	NO	>9	6-9
24	>9	NO	6-9	6-9	>9	>9	6-9	6-9	NO	>9	>9	6-9	>9	>9
25	>9	NO	NO	>9	NO	6-9	NO	NO	NO	NO	>9	>9	>9	>9
26	6-9	NO	3-6	6-9	6-9	6-9	NO	NO	NO	6-9	6-9	6-9	6-9	6-9
27	>9	NO	NO	<3	NO	>9	NO	NO	NO	NO	3-6	>9	>9	>9
28	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	>9	3-6	>9
29	>9	NO	>9	NO	NO	NO	NO	NO	NO	>9	>9	>9	>9	>9
30	>9	NO	>9	NO	>9	>9	3-6	NO	NO	NO	>9	>9	>9	>9

Supplemental Table 1 (continuation).

Patient's ID	Long-COVID signs and symptoms											Current treatments at the time of sampling
	Depression	Anxiety	Insomnia	Coagulopathy	Petechiae	Palpitations	Myocarditis/pericarditis	Arrhythmia	Urine infection	Nail changes	Alopecia	
1	NO	NO	>9	NO	NO	>9	NO	>9	NO	NO	NO	Etonogestrel-ethinyl estradiol, buprenorphine, cetirizine, enoxaparin, bisoprolol, ivabradine, cholecalciferol, lorazepam, tramadol
2	NO	NO	NO	NO	3-6	>9	NO	NO	NO	NO	3-6	NO
3	NO	NO	>9	NO	NO	NO	NO	>9	NO	NO	3-6	Methotrexate, sulfasalazine, levothyroxine, folic acid
4	6-9	3-6	3-6	NO	NO	6-9	NO	NO	NO	NO	6-9	Rosuvastatin
5	>9	3-6	NO	>9	NO	NO	<3	NO	NO	NO	>9	NO
6	>9	>9	>9	NO	3-6	<3	3-6	NO	NO	>9	6-9	NO
7	>9	>9	<3	NO	>9	3-6	NO	NO	NO	6-9	6-9	Esomeprazole
8	6-9	NO	6-9	NO	NO	6-9	NO	NO	<3	6-9	NO	Paracetamol, tramadol, ibuprofen, naproxen
9	>9	>9	>9	<3	NO	>9	NO	NO	NO	NO	NO	Salbutamol
10	6-9	NO	NO	NO	NO	>9	NO	NO	NO	NO	6-9	Budesonide/formoterol, ipratropium bromide, pantoprazole, bromazepam
11	>9	>9	>9	NO	>9	>9	NO	>9	NO	NO	>9	Azathioprine, chloroquine, acetylsalicylic acid, escitalopram, cholecalciferol
12	>9	NO	>9	<3	NO	>9	NO	NO	NO	NO	NO	NO
13	NO	<3	3-6	<3	3-6	>9	NO	NO	NO	NO	>9	NO
14	>9	>9	6-9	NO	3-6	3-6	NO	NO	NO	3-6	3-6	Levothyroxine, folic acid, amitriptyline, deflazacort, hydroxychloroquine, omeprazole, cholecalciferol
15	NO	NO	>9	NO	>9	>9	NO	NO	>9	NO	>9	Levothyroxine, duloxetine
16	>9	>9	NO	NO	NO	>9	NO	NO	NO	NO	NO	Duloxetine, omeprazol, amitriptyline, zolpidem
17	>9	>9	>9	NO	NO	>9	NO	NO	NO	6-9	6-9	Desogestrel/ethinyl estradiol
18	NO	NO	3-6	3-6	NO	>9	NO	>9	<3	NO	6-9	NO
19	NO	NO	NO	NO	NO	NO	NO	3-6	NO	NO	NO	NO
20	3-6	NO	<3	NO	NO	3-6	NO	NO	NO	NO	3-6	NO
21	>9	>9	NO	NO	NO	>9	NO	>9	6-9	NO	NO	Dexketoprofen, acetaminophen, omeprazole, cholecalciferol
22	6-9	6-9	3-6	NO	NO	>9	NO	NO	NO	NO	NO	levothyroxine
23	NO	NO	>9	NO	<3	>9	NO	>9	NO	<3	<3	Drospirenone/ethinyl estradiol, cholecalciferol, acetaminophen, ibuprofen
24	NO	NO	>9	NO	<3	>9	NO	NO	NO	NO	NO	Flunarizine, pregabalin, zolpidem, mirtazapine
25	3-6	NO	<3	NO	NO	<3	NO	<3	NO	NO	6-9	Levothyroxine, acetylsalicylic acid, cholecalciferol, atorvastatin, amiloride/hydrochlorothiazide
26	6-9	6-9	3-6	NO	6-9	6-9	NO	NO	NO	6-9	NO	Fluticasone/formoterol, tiotropium bromide, sertraline, paracetamol
27	6-9	6-9	6-9	NO	NO	6-9	6-9	6-9	6-9	NO	>9	Levothyroxine, cholecalciferol, ferrous sulfate, vitamin B12
28	>9	>9	3-6	NO	NO	NO	NO	NO	NO	NO	NO	NO
29	NO	NO	NO	NO	6-9	NO	NO	NO	NO	NO	3-6	Acetylsalicylic acid, folic acid, vitamins B1-B6-B12
30	NO	NO	>9	NO	NO	>9	NO	NO	NO	NO	3-6	Diltiazem, enalapril, atorvastatin, lorazepam